446 related articles for article (PubMed ID: 22665726)
21. Sex differences in in vitro pro-inflammatory cytokine production from peripheral blood of multiple sclerosis patients.
Nguyen LT; Ramanathan M; Weinstock-Guttman B; Baier M; Brownscheidle C; Jacobs LD
J Neurol Sci; 2003 May; 209(1-2):93-9. PubMed ID: 12686409
[TBL] [Abstract][Full Text] [Related]
22. Cortical dysfunction underlies disability in multiple sclerosis.
Vucic S; Burke T; Lenton K; Ramanathan S; Gomes L; Yannikas C; Kiernan MC
Mult Scler; 2012 Apr; 18(4):425-32. PubMed ID: 21965421
[TBL] [Abstract][Full Text] [Related]
23. Longitudinal patterns of cortical thinning in multiple sclerosis.
Tsagkas C; Chakravarty MM; Gaetano L; Naegelin Y; Amann M; Parmar K; Papadopoulou A; Wuerfel J; Kappos L; Sprenger T; Magon S
Hum Brain Mapp; 2020 Jun; 41(8):2198-2215. PubMed ID: 32067281
[TBL] [Abstract][Full Text] [Related]
24. Anti-SPAG16 antibodies in primary progressive multiple sclerosis are associated with an elevated progression index.
de Bock L; Fraussen J; Villar LM; Álvarez-Cermeño JC; Van Wijmeersch B; van Pesch V; Stinissen P; Somers V
Eur J Neurol; 2016 Apr; 23(4):722-8. PubMed ID: 26706657
[TBL] [Abstract][Full Text] [Related]
25. Volume loss in the deep gray matter and thalamic subnuclei: a longitudinal study on disability progression in multiple sclerosis.
Magon S; Tsagkas C; Gaetano L; Patel R; Naegelin Y; Amann M; Parmar K; Papadopoulou A; Wuerfel J; Stippich C; Kappos L; Chakravarty MM; Sprenger T
J Neurol; 2020 May; 267(5):1536-1546. PubMed ID: 32040710
[TBL] [Abstract][Full Text] [Related]
26. Natural history of secondary-progressive multiple sclerosis.
Tremlett H; Yinshan Zhao ; Devonshire V
Mult Scler; 2008 Apr; 14(3):314-24. PubMed ID: 18208898
[TBL] [Abstract][Full Text] [Related]
27. Clinically relevant cranio-caudal patterns of cervical cord atrophy evolution in MS.
Rocca MA; Valsasina P; Meani A; Gobbi C; Zecca C; Rovira À; Montalban X; Kearney H; Ciccarelli O; Matthews L; Palace J; Gallo A; Bisecco A; Gass A; Eisele P; Lukas C; Bellenberg B; Barkhof F; Vrenken H; Preziosa P; Comi G; Filippi M;
Neurology; 2019 Nov; 93(20):e1852-e1866. PubMed ID: 31611336
[TBL] [Abstract][Full Text] [Related]
28. The effects of thrombomodulin and activated protein C on the pathogenesis of multiple sclerosis.
Balkuv E; Varoglu AO; Isik N; Isbilen B; Duruyen S; Basaran R; Kocer A
Mult Scler Relat Disord; 2016 Jul; 8():131-5. PubMed ID: 27456888
[TBL] [Abstract][Full Text] [Related]
29. A reassessment of the plateauing relationship between T2 lesion load and disability in MS.
Sormani MP; Rovaris M; Comi G; Filippi M
Neurology; 2009 Nov; 73(19):1538-42. PubMed ID: 19794123
[TBL] [Abstract][Full Text] [Related]
30. Staging of cortical and deep grey matter functional connectivity changes in multiple sclerosis.
Meijer KA; Eijlers AJC; Geurts JJG; Schoonheim MM
J Neurol Neurosurg Psychiatry; 2018 Feb; 89(2):205-210. PubMed ID: 28986469
[TBL] [Abstract][Full Text] [Related]
31. NfL predicts relapse-free progression in a longitudinal multiple sclerosis cohort study.
Uphaus T; Steffen F; Muthuraman M; Ripfel N; Fleischer V; Groppa S; Ruck T; Meuth SG; Pul R; Kleinschnitz C; Ellwardt E; Loos J; Engel S; Zipp F; Bittner S
EBioMedicine; 2021 Oct; 72():103590. PubMed ID: 34571362
[TBL] [Abstract][Full Text] [Related]
32. MRI-detectable cortical lesions in the cerebellum and their clinical relevance in multiple sclerosis.
Favaretto A; Lazzarotto A; Poggiali D; Rolma G; Causin F; Rinaldi F; Perini P; Gallo P
Mult Scler; 2016 Apr; 22(4):494-501. PubMed ID: 26163070
[TBL] [Abstract][Full Text] [Related]
33. How effective are disease-modifying drugs in delaying progression in relapsing-onset MS?
Brown MG; Kirby S; Skedgel C; Fisk JD; Murray TJ; Bhan V; Sketris IS
Neurology; 2007 Oct; 69(15):1498-507. PubMed ID: 17699802
[TBL] [Abstract][Full Text] [Related]
34. Cervical cord lesion load is associated with disability independently from atrophy in MS.
Kearney H; Altmann DR; Samson RS; Yiannakas MC; Wheeler-Kingshott CA; Ciccarelli O; Miller DH
Neurology; 2015 Jan; 84(4):367-73. PubMed ID: 25540312
[TBL] [Abstract][Full Text] [Related]
35. Involvement of cytotoxic Eomes-expressing CD4
Raveney BJE; Sato W; Takewaki D; Zhang C; Kanazawa T; Lin Y; Okamoto T; Araki M; Kimura Y; Sato N; Sano T; Saito Y; Oki S; Yamamura T
Proc Natl Acad Sci U S A; 2021 Mar; 118(11):. PubMed ID: 33836594
[TBL] [Abstract][Full Text] [Related]
36. Sera from remitting and secondary progressive multiple sclerosis patients disrupt the blood-brain barrier.
Shimizu F; Tasaki A; Sano Y; Ju M; Nishihara H; Oishi M; Koga M; Kawai M; Kanda T
PLoS One; 2014; 9(3):e92872. PubMed ID: 24686948
[TBL] [Abstract][Full Text] [Related]
37. Treatment effects of immunomodulatory therapies at different stages of multiple sclerosis in short-term trials.
Bates D
Neurology; 2011 Jan; 76(1 Suppl 1):S14-25. PubMed ID: 21205678
[TBL] [Abstract][Full Text] [Related]
38. Composite Marker of Cognitive Dysfunction and Brain Atrophy is Highly Accurate in Discriminating Between Relapsing-Remitting and Secondary Progressive Multiple Sclerosis.
Kizlaitienė R; Kaubrys G; Giedraitienė N; Ramanauskas N; Dementavičienė J
Med Sci Monit; 2017 Feb; 23():588-597. PubMed ID: 28145395
[TBL] [Abstract][Full Text] [Related]
39. Evaluation of antioxidant parameters of multiple sclerosis patients' serum according to the disease course.
Nowak-Kiczmer M; Niedziela N; Zalejska-Fiolka J; Adamczyk-Sowa M
Mult Scler Relat Disord; 2023 Sep; 77():104875. PubMed ID: 37454567
[TBL] [Abstract][Full Text] [Related]
40. Detection of cortical inflammatory lesions by double inversion recovery magnetic resonance imaging in patients with multiple sclerosis.
Calabrese M; De Stefano N; Atzori M; Bernardi V; Mattisi I; Barachino L; Morra A; Rinaldi L; Romualdi C; Perini P; Battistin L; Gallo P
Arch Neurol; 2007 Oct; 64(10):1416-22. PubMed ID: 17923625
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
